U.S. District Court Upholds Validity of Lilly's Alimta Patent Through 2022 (NYSE:LLY)

INDIANAPOLIS, March 31, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana has ruled in the company's favor regarding the vitamin dosage regimen patent for Alimta^® (pemetrexed for injection). In the case of Eli Lilly and Company v. Teva Parenteral Medicines Inc., et al., the court ruled the vitamin dosage regimen patent is valid and enforceable. The patent provides intellectual property protection for Alimta until 2022.  Alimta's compound patent remains in force through early 2017.



U.S. District Court Upholds Validity of Lilly's Alimta Patent Through 2022 (NYSE:LLY)